Takada Junichi, Iba Kousuke, Yamashita Toshihiko
Kitago Orthopaedic Clinic/Department of Orthopaedic Surgery, Sapporo Medical University.
Clin Calcium. 2011 Jul;21(7):1047-55.
The effectiveness of selective estrogen receptor modulator (SERM) in X-ray, dual X-ray Absorptiometry (DXA), quantitative computed tomography (QCT), and hip structure analysis (HSA) are reviewed. Raloxifene and bazedoxifene increase bone mineral density in the spine and femoral neck, and reduce risk of vertebral fracture in women with osteoporosis, and reduce risk of nonvertebral fractures in women with higher fracture risk. Raloxifene improved bone density and micro architecture in spine and limbs (distal radius and distal tibia) represented by volumetric QCT and high-resolution peripheral QCT. Raloxifene also improved HSA parameters in femoral neck, intertrochanter, and shaft regions. The tendency to change in these parameters is approximately similar in raloxifene and bisphosphonates (alendronate, risedronate, minodronate). These results indicate that raloxifene improved the bone density and bone quality in spine, limbs and hip.
本文综述了选择性雌激素受体调节剂（SERM）在X线、双能X线吸收法（DXA）、定量计算机断层扫描（QCT）以及髋部结构分析（HSA）方面的有效性。雷洛昔芬和巴多昔芬可增加脊柱和股骨颈的骨密度，降低骨质疏松症女性的椎体骨折风险，并降低骨折风险较高女性的非椎体骨折风险。雷洛昔芬通过容积QCT和高分辨率外周QCT改善了脊柱和四肢（桡骨远端和胫骨远端）的骨密度和微观结构。雷洛昔芬还改善了股骨颈、转子间和骨干区域的HSA参数。雷洛昔芬和双膦酸盐（阿仑膦酸钠、利塞膦酸钠、米诺膦酸）在这些参数上的变化趋势大致相似。这些结果表明，雷洛昔芬改善了脊柱、四肢和髋部的骨密度和骨质。
